Providing the full picture: a mandate for standardizing nanoparticle-based drug delivery.

1031 ISSN 1743-5889 10.2217/NNM.13.95 © 2013 Future Medicine Ltd Nanomedicine (2013) 8(7), 1031–1033 “What is needed in the field is a set of nanoparticle physicochemical characterization and biological evaluation criteria that allow not only the author, but also the reader, to fully understand the mechanism of activity, interpret experimental data and bring standardization that is required for clinical translation to the field.”

[1]  T. Kirchhausen,et al.  Dynasore, a cell-permeable inhibitor of dynamin. , 2006, Developmental cell.

[2]  S Moein Moghimi,et al.  Complement: alive and kicking nanomedicines. , 2009, Journal of biomedical nanotechnology.

[3]  J. Kjems,et al.  Nanocarrier stimuli-activated gene delivery. , 2007, Small.

[4]  J. Kjems,et al.  Size-Dependent Accumulation of PEGylated Silane-Coated Magnetic Iron Oxide Nanoparticles in Murine Tumors. , 2009, ACS nano.

[5]  V. Murthy,et al.  Inhibition of dynamin completely blocks compensatory synaptic vesicle endocytosis , 2006, Proceedings of the National Academy of Sciences.

[6]  Thomas Vorup-Jensen,et al.  Curvature of Synthetic and Natural Surfaces Is an Important Target Feature in Classical Pathway Complement Activation , 2010, The Journal of Immunology.

[7]  Dan Peer,et al.  The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. , 2010, Biomaterials.

[8]  Dan Peer,et al.  Altering the immune response with lipid-based nanoparticles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[9]  K. G. Rajeev,et al.  Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  D. Peer,et al.  Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target , 2008, Science.

[11]  Michael S. Goldberg,et al.  Development of lipidoid-siRNA formulations for systemic delivery to the liver. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  J. Kjems,et al.  The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. , 2007, Biomaterials.

[13]  Dan Peer,et al.  Nanoparticle hydrophobicity dictates immune response. , 2012, Journal of the American Chemical Society.

[14]  J. Kjems,et al.  Peritoneal macrophages mediated delivery of chitosan/siRNA nanoparticle to the lesion site in a murine radiation-induced fibrosis model , 2013, Acta oncologica.

[15]  P. Kingshott,et al.  Surface Analysis of PEGylated Nano-Shields on Nanoparticles Installed by Hydrophobic Anchors , 2013, Pharmaceutical Research.

[16]  Vasco Filipe,et al.  Critical Evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the Measurement of Nanoparticles and Protein Aggregates , 2010, Pharmaceutical Research.

[17]  J. Kjems,et al.  Intracellular siRNA and precursor miRNA trafficking using bioresponsive copolypeptides , 2008, The journal of gene medicine.

[18]  Kenneth A Howard,et al.  RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  T. Kirchhausen,et al.  Single-molecule live-cell imaging of clathrin-based endocytosis. , 2005, Biochemical Society symposium.

[20]  Dan Peer,et al.  A daunting task: manipulating leukocyte function with RNAi , 2013, Immunological reviews.

[21]  Seyed Moein Moghimi,et al.  Liposome triggering of innate immune responses: A perspective on benefits and adverse reactions , 2009, Journal of liposome research.

[22]  D. Peer.  Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. , 2012, Advanced drug delivery reviews.